251 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
INCY Incyte Corporation $67.04 $14.25B N/A
Article Searches
Drug Stocks Q1 Earnings to Watch on May 1: PFE, MRK & More http://www.zacks.com/stock/news/301466/drug-stocks-q1-earnings-to-watch-on-may-1-pfe-mrk-more?cid=CS-ZC-FT-301466 Apr 30, 2018 - Four pharma/biotech companies are set to release earnings report on May 1. Let's take a look into how the companies are placed ahead of the upcoming results.
Should You Sell Incyte (INCY) Before Earnings? http://www.zacks.com/stock/news/301381/should-you-sell-incyte-incy-before-earnings?cid=CS-ZC-FT-301381 Apr 30, 2018 - Incyte (INCY) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to earnings beat.
Can Jafaki Help Incyte (INCY) Beat Earnings Estimates in Q1? http://www.zacks.com/stock/news/301187/can-jafaki-help-incyte-incy-beat-earnings-estimates-in-q1?cid=CS-ZC-FT-301187 Apr 27, 2018 - Incyte (INCY) is likely to beat on earnings when it reports first-quarter results on May 1 driven by strong Jakafi sales.
Biotech Stock Roundup: PRTA Down, AMGN Revises View, BIIB Misses on Sales http://www.zacks.com/stock/news/300782/biotech-stock-roundup-prta-down-amgn-revises-view-biib-misses-on-sales?cid=CS-ZC-FT-300782 Apr 25, 2018 - The biotech sector grabbed headlines last week as a couple of biotechs reported results while few others came out with pipeline updates.
Lessons to Learn From April's Biotech Blowups https://www.fool.com/investing/2018/04/25/lessons-to-learn-from-aprils-biotech-blowups.aspx?source=iedfolrf0000001 Apr 25, 2018 - Three biotechs reported devastating clinical trial failures this month. Here are the important takeaways.
Is Eli Lilly and Company a Buy? https://www.fool.com/investing/2018/04/25/is-eli-lilly-and-company-a-buy.aspx?source=iedfolrf0000001 Apr 25, 2018 - Lilly's first-quarter results looked good. Is it time to buy the big pharma stock?
Lilly (LLY) Tops on Q1 Earnings, Raises '18 View, Stock Up http://www.zacks.com/stock/news/300433/lilly-lly-tops-on-q1-earnings-raises-18-view-stock-up?cid=CS-ZC-FT-300433 Apr 24, 2018 - Eli Lilly (LLY) beats estimates for both earnings and sales in Q1 and raises guidance for 2018. Shares rise in pre-market trading.
3 Biotech Stocks With Major Catalysts Incoming https://www.fool.com/investing/2018/04/20/3-biotech-stocks-with-huge-catalysts-incoming.aspx?source=iedfolrf0000001 Apr 20, 2018 - Highly anticipated events expected in the weeks ahead could set these three biotechs up for long-term success.
Lilly (LLY) to Report Q1 Earnings: What's in the Cards? http://www.zacks.com/stock/news/300046/lilly-lly-to-report-q1-earnings-whats-in-the-cards?cid=CS-ZC-FT-300046 Apr 20, 2018 - Lilly's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.
What Incyte's Phase 3 Fail Means for Immuno-Oncology https://www.fool.com/investing/2018/04/16/what-incytes-phase-3-fail-means-for-immuno-oncolog.aspx?source=iedfolrf0000001 Apr 16, 2018 - Incyte’s phase 3 Epacadostat trial wasn’t so hot, and stocks all across biotech are feeling the burn.

Pages: 1...4567891011121314...26

<<<Page 9>